What Is Semaglutide? Weight Management Entries and Pathways
GLP-1 / GIP / GCG / amylin pathways. For mechanism explanations see GLP-1 Drugs.
Mechanisms and Research Highlights
Section titled “Mechanisms and Research Highlights”The core of weight loss and glucose control is not “stronger appetite suppression” but choosing the right pathway + body composition protection:
| User pain point | Pathway choice | Ingredient/blend |
|---|---|---|
| Simply eating less, hungry easily | GLP-1 | Semaglutide / Liraglutide |
| Not enough magnitude, plateau | GIP+GLP-1 | Tirzepatide |
| Extreme severity, needs energy expenditure | +GCGR | Retatrutide |
| Appetite rebounds on GLP-1 alone | +Amylin | Cagrilintide in combination |
Clear pathways help estimate effects and cycles; fixed ratios make stage-by-stage comparison easier.
Tirzepatide
Section titled “Tirzepatide”A GIP/GLP-1 dual-receptor agonist.
| Attribute | Value |
|---|---|
| Spec code | TR60 / TR30 / TR15 / TR10 |
| Specs | 60 / 30 / 15 / 10mg |
| Mechanism | GLP-1/GIP dual-receptor agonist |
| Scenario | High body weight, glucose control and weight loss, plateau |
Mechanistically overlaps with Semaglutide, Retatrutide, and TR30CAG5; read side by side. For the full mechanism description see GLP-1 Drugs. Related to the problem scenarios in Weight-Loss Plateau.
Retatrutide
Section titled “Retatrutide”A triple-receptor agonist; thermogenesis and energy expenditure.
| Attribute | Value |
|---|---|
| Spec code | RT30 / RT20 / RT10 |
| Specs | 30 / 20 / 10mg |
| Mechanism | GLP-1/GIP/GCGR triple receptor, thermogenesis and energy expenditure |
| Scenario | Severe obesity, hepatic fat research frontier |
Mechanistically overlaps with Tirzepatide and RT15CAG5; read side by side.
Semaglutide
Section titled “Semaglutide”A long-acting GLP-1 receptor agonist.
| Attribute | Value |
|---|---|
| Spec code | SM10 / SM5 / SM2 |
| Specs | 10 / 5 / 2mg |
| Mechanism | Long-acting GLP-1, delays gastric emptying, central appetite suppression |
| Scenario | Glucose control and fat loss, the most widely used GLP-1 |
Mechanistically overlaps with Cagrilintide, Liraglutide, and SM5CAG5; read side by side.
Cagrilintide
Section titled “Cagrilintide”An amylin analog.
| Attribute | Value |
|---|---|
| Spec code | CAG10 / CAG5 |
| Specs | 10 / 5mg |
| Mechanism | Long-acting amylin analog, satiety + suppression of inappropriate glucagon |
| Scenario | Dual-pathway appetite suppression in combination with GLP-1 |
Mechanistically overlaps with Semaglutide and SM5CAG5; read side by side.
Mazdutide
Section titled “Mazdutide”A GLP-1/GCG dual-receptor agonist.
| Attribute | Value |
|---|---|
| Spec code | MZ30 / MZ10 |
| Specs | 30 / 10mg |
| Mechanism | GLP-1/GCG dual-receptor agonist |
| Scenario | Controls appetite while maintaining basal metabolic rate |
Mechanistically overlaps with Tirzepatide and Semaglutide; read side by side.
Liraglutide
Section titled “Liraglutide”A daily GLP-1 receptor agonist.
| Attribute | Value |
|---|---|
| Spec code | LIRA18 |
| Specs | 18mg |
| Mechanism | Short-half-life daily GLP-1 |
| Scenario | Weight and glucose management with fine dose titration |
Mechanistically related to Semaglutide.
Quality Control and Label Comparison (General)
Section titled “Quality Control and Label Comparison (General)”| Item | Notes |
|---|---|
| Identification | HPLC/MS |
| Purity/assay | ≥ specification (follow pharmacopoeia/registered standards) |
| Label dosing | Follow each country’s registered label; this site does not give prescriptions |
| Molecular weight/salt form | Affects stability and manufacturing process |
For research and teaching cross-reference only; not medical guidance.
Pathway Comparison
Section titled “Pathway Comparison”| Pathway | Ingredient | Characteristics |
|---|---|---|
| GLP-1 | Semaglutide, Liraglutide | Appetite, gastric emptying |
| GIP+GLP-1 | Tirzepatide | Greater magnitude |
| Triple target | Retatrutide | Thermogenesis and energy expenditure |
| Amylin | Cagrilintide | Used with GLP-1 |
| GLP-1+GCG | Mazdutide | Metabolic rate maintenance |
Key References
Section titled “Key References”For STEP / SURMOUNT and head-to-head data see the GLP-1 Comparison; network meta-analysis PMID: 39305981.
Priorities in Weight-Loss Strategy
Section titled “Priorities in Weight-Loss Strategy”Choosing among weight-management entries follows the order “pathway → body composition → tolerance”, not the scale number alone.
GI Tolerance and Titration
Section titled “GI Tolerance and Titration”The common limiting factor for GLP-1-class objects is gastrointestinal tolerance; titrating gradually per label and medical advice, and giving the body time to adapt, is more sustainable than ramping fast. Background on insulin sensitivity is in Insulin Resistance.
Rate of Loss and Body Composition
Section titled “Rate of Loss and Body Composition”Weight loss is not the same as fat loss; rapid loss often comes with lean-mass loss, and protein intake plus resistance training are protective measures (see GLP-1 and Muscle Preservation). How to read plateaus is in Weight-Loss Plateau, and fat distribution in Visceral Fat.
This page is for research and teaching reference only and does not constitute medical advice or dosing guidance; for prescription drugs, indications, doses, and contraindications follow the label and a physician’s guidance.
Related Reading
Section titled “Related Reading”Safety Boundaries and Limitations
Section titled “Safety Boundaries and Limitations”Indications, doses, and contraindications follow the label and medical advice. Research-grade and pharmaceutical-grade specs must not be mixed.
Practical workflow and quality control: before using or comparing an ingredient, see reconstitution, storage, COA, and administration routes; operating standards in Peptide Basics.